沙库巴曲缬沙坦联合松龄血脉康胶囊治疗老年高血压病合并慢性心力衰竭的疗效  

Effects of sacubitril valsartan combined with Songling Xuemaikang capsules for elderly patients with hy-pertension and chronic heart failure

作　　者：朱逸琪 沈伟英 张益锋 Zhu Yiqi;Shen Weiying;Zhang Yifeng(Department of Cardiology,Third People′s Hospital of Cixi City,Cixi,Zhejiang 315315,China;Department ofCardiology,Guanhaiwei Branch of Medical and Health Group,Cixi People′s Hospital,Cixi,Zhejiang 315315,China)

机构地区：[1]慈溪市第三人民医院心内科,浙江慈溪315315 [2]慈溪市人民医院医疗健康集团观海卫分院心内科,浙江慈溪315315

出　　处：《中国药物与临床》2024年第7期421-427,共7页Chinese Remedies & Clinics

摘　　要：目的探讨沙库巴曲缬沙坦联合松龄血脉康胶囊治疗对老年高血压病合并慢性心力衰竭(HF)患者的临床效果。方法回顾性纳入2021年1月1日至2023年3月1日浙江省慈溪市第三人民医院收治的106例高血压病合并慢性HF的老年患者(年龄≥60岁),所有患者均已接受高血压病和慢性HF的常规治疗和沙库巴曲缬沙坦治疗。根据患者是否接受松龄血脉康胶囊治疗,分为沙库巴曲缬沙坦联合松龄血脉康治疗组(39例)和沙库巴曲缬沙坦组(67例)。所有患者随访6个月,比较治疗前后24 h平均收缩压、24 h平均舒张压、心率、血清低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、同型半胱氨酸(Hcy)、左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室后壁厚度(LVPWT)、氨基末端脑利钠肽前体(NT-proBNP)等指标的变化。评估2组患者治疗期间不良反应有无差异。结果2组患者治疗后24 h平均收缩压、24 h平均舒张压均降低(t=6.06、8.95、4.33、5.19,P均<0.01),且沙库巴曲缬沙坦联合松龄血脉康治疗组治疗后较沙库巴曲缬沙坦组下降更为明显(t=6.92、5.18,P<0.05)。2组患者治疗后对心率均无影响(P>0.05)。2组患者治疗后LDL-C和TG有所降低(t=2.33、1.87、3.01、2.92,P均<0.05),且沙库巴曲缬沙坦联合松龄血脉康治疗组治疗后较沙库巴曲缬沙坦组下降更为明显(t=2.10、2.46,P<0.05)。2组患者治疗后Hcy均有改善(t=2.62、1.90,P均<0.05),且沙库巴曲缬沙坦联合松龄血脉康治疗组治疗后较沙库巴曲缬沙坦组下降更为明显(t=2.08,P<0.05)。2组患者治疗后LVEF均有明显升高(t=6.08、5.37,P均<0.01),且沙库巴曲缬沙坦联合松龄血脉康治疗组治疗后改善效果略微显著(t=5.67,P=0.04)。2组患者治疗后LVEDD、LVESD和LVPWT均降低(t=5.39、5.27、3.86、3.17、1.58、1.21,P均<0.05),但2组之间比较差异无统计学意义(P>0.05)。2组患者治疗后NT-proBNP均�Objective To explore the clinical effect of the combination of sacubitril valsartan and Songling Xuemaikang capsules for elderly patients with hypertension and chronic heart failure(HF).Methods A retrospective study was conducted on 106 elderly patients(aged≥60 years)with hypertension and chronic HF admitted to our hospital from January 1,2021 to March 1,2023.All patients have received routine treatment for hypertension and chronic HF,as well as treatment with sacubitril and valsartan.According to whether the patient received additional treatment with Songling Xuemaikang capsules(1.5 g each time,3 times a day,orally),they were divided into two groups:the sacubitril valsartan combined with Songling Xuemaikang treatment group(n=39)and the sacubitril valsartan group(n=67).Two groups of patients were followed up for 6 months,during which they received corresponding treatment.Baseline characteristics of two groups of patients were collected and compared their 24-hour mean systolic blood pressure levels,24-hour mean diastolic blood pressure levels,heart rate levels,serum low-density lipoprotein cholesterol(LDL-C)levels,triglyceride levels(TG),homocysteine levels(Hcy),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),left ventricular posterior wall thickness(LVPWT),and N-terminal Pro Brain Natriuretic Peptide(NT-proBNP).Evaluate whether there are differences in adverse reactions between the two groups during treatment period.Results The 24-hour mean systolic blood pressure level and 24-hour mean diastolic blood pressure in both groups decreased significantly after treatment(t=6.06、8.95、4.33、5.19,P<0.01),and the sacubitril valsartan and Songling Xuemaikang treatment group showed a more significant decrease compared to the sacubitril valsartan group(t=6.92、5.18,P<0.05).Both groups had no effect on heart rate after treatment(P>0.05).After treatment,LDL-C and TG levels decreased in both groups(t=2.33、1.87、3.01、2.92,P<0.05),an

关 键 词：松龄血脉康胶囊 老年人 高血压 心力衰竭 

分 类 号：R969[医药卫生—药理学] R544.1[医药卫生—药学] R541.6